Latest Conference Articles

The WARRIOR trial provides insight into intensive medical therapy in women with INOCA, but investigators caution limitations hinder the applicability of results.

Data from STRIDE at ACC.25 demonstrate semaglutide could provide even greater benefits in type 2 diabetes than previously known.

A look at 7 phase 2 and phase 3 trials with significant implications from ACC 2025's late-breaking and featured clinical research sessions.

Kwo explains why hepatitis A and B vaccination is important for people with liver disease and reviews different vaccine options.

Dara explains the importance of distinguishing DI-ALH from classic AIH, how their management differs, and where research in this field is heading.

Tabrizian discusses neoadjuvant immunotherapy for HCC, describing its success in the adjuvant setting but uncertainties about its use before transplant.

Dara describes similarities between drug-induced autoimmune-like hepatitis and idiopathic autoimmune hepatitis, as well as how to differentiate them.

Martinez explains the benefit of IBAT inhibitors for improving pruritus in children with Alagille syndrome and PFIC.

Goel describes the clinical impact of having 2 newly approved second-line PBC therapies and looks ahead to what’s next and where more research is needed.

Positive topline results from PORTOLA show treatment with zetomipzomib resulted in steroid-sparing biochemical remissions in AIH.

Mitchell reviews FDA-approved drugs for reducing alcohol use, which ones can be used in patients with liver disease, and other therapies on the horizon.

Khandelwal discusses advancements in intraocular lens (IOL) categories and the patient's role in choosing more innovative options.

Schilsky describes lingering challenges and unmet needs in Wilson disease and highlights recent innovations in monitoring and diagnosis.

Khandelwal shares insight and key takeaways for the optimization of intraocular lens selection in practice.

Repka describes the complications of the US healthcare system and how to advance interactions in advocacy efforts.

Goel explains the importance of second-line therapies and describes the role PPARs play in PBC treatment, including 2 newly approved therapies.

Repka dives into the role of advocacy in shaping ophthalmologic policies and ensuring equitable patient care.

Lammert describes the clinical impact of having 2 new second-line PBC therapies, challenges to their uptake, and areas where more research is needed.

Saab describes historical and ongoing unmet needs in Wilson disease, highlighting recent progress but also the need for a streamlined diagnosis.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key allergy updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.

Lammert discusses the shifting landscape of treatment response metrics and the latest advancements in second-line therapy for PBC.

Martinez explains the pathophysiology and clinical presentation of pruritus in children with cholestatic liver disease as well as treatment options.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode highlights 5 key dermatology updates from the 2025 American Academy of Dermatology Annual Meeting in Orlando.

Schilsky provides an overview of Wilson disease and describes optimal management strategies, highlighting the importance of early detection and intervention.

Mitchell describes the “paradox” hepatologists face in the management of ALD and the importance of early intervention for improving outcomes.

These data highlight the potential benefit of continuous treatment with subcutaneous spesolimab for generalized pustular psoriasis (GPP).

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.